BUSINESS

• Kyowa Kirin, Medgenics Team Up on Severe Pediatric IBD Treatment
  June 8, 2016

• FY2015 Earnings Roundup - 3: Japan Market Stagnates despite No Drug Price Revision, Off-Patent Brands Weigh
  June 8, 2016

• Takeda, Roivant Form Joint Venture for Women’s Health, Prostate Cancer; Takeda Transfers 2 Investigational Products
  June 8, 2016

• FY2015 Earnings Roundup - 2: New Drugs Gain Traction Overseas to Underpin Japan Makers’ Financial Results
  June 7, 2016

• PDUFA Date for Naldemedine Set for March 23, 2017
  June 7, 2016

• Takecab Most Promoted Drug for 4 Months on End: Anterio
  June 7, 2016

• FY2015 Earnings Roundup - 1: Operating Profits of Japan Makers Climb on Global Brands, Royalties
  June 6, 2016

• Eisai, Novartis to Join Forces in US Lenvima Promotion for Kidney Cancer
  June 6, 2016

• Astellas to Kick Off Global PIII on Xtandi for Triple-Negative Breast Cancer
  June 6, 2016

• 27 Japan Drug Makers Derive Record 45.8% of Sales from Overseas Market: Jiho Tally
  June 3, 2016

• AbbVie, EA Pharma Initiate Copromotion of Humira in GI Field
  June 3, 2016

• Terano Tapped as President of Japan Vaccine
  June 2, 2016

• Chugai Licenses Antibody SA237 to Roche, Japan Filing Slated for 2018
  June 2, 2016

• Ex-Boehringer Japan Pres. Torii to Head Novartis Holdings Japan
  June 2, 2016

• After Tax Hike Delay, Industry Officials Vigilant about Price Slash for Innovative Drugs
  June 2, 2016

• Meiji Plans Japan-Bound Generic Projection in India to Seek Cost Competitiveness
  June 1, 2016

• Meiji Seika Pharma Pins High Hopes on Schizophrenia Drug Sycrest
  June 1, 2016

• Daiichi Sankyo Ceases Development of Patritumab for NSCLC
  June 1, 2016

• Oncolys Concludes Option Agreement with US CRO for HIV Treatment Censavudine
  June 1, 2016

• Takeda Consumer Healthcare Unit Aims for 100 Billion Yen Sales after Spin-Off
  May 31, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 469
• 470
• 471
• 472
• 473
• 474
• 475
• 476
• 477
• …
• Next ›
• 最終 »